Strides Pharma Science Limited (STAR.BO)
Strides Pharma Science Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Bengaluru, KA, IN. The stock last traded at $968.05, down 1.75% on the session, giving a market capitalisation of $88.94B. Its beta of 0.39 implies it has historically moved less than the broad market.
Established in 1990 and based in Bengaluru, India, Strides Pharma Science Limited operates as an international pharmaceutical company, involved in the creation, production, and sale of a wide array of pharmaceutical products. Its operations span numerous global markets, including Africa, Australia, North America, Europe, Asia, and India, and are structured into two main divisions: Pharmaceutical and Biopharmaceutical. The company's portfolio encompasses a comprehensive selection of generic pharmaceuticals, offered in various dosage forms such as tablets, hard and soft gelatin capsules, sachets, liquids, nasal sprays, powders, solids, ointments, and creams. Additionally, Strides Pharma Science develops and markets branded generic products targeting chronic conditions across therapeutic areas like women's health, central nervous system disorders, cardiovascular diseases, diabetes, dermatology, and probiotics, under recognized brands including Renerve, Unibrol, Combiart, Duotab, and Vitafer. Its institutional business also provides essential medications for infectious diseases, such as anti-retrovirals, anti-malarials, anti-tuberculosis drugs, and Hepatitis treatments. A key collaboration with Orbicular Pharmaceutical Technologies Private Limited focuses on the joint development, manufacturing, and commercialization of nasal spray formulations. The company adopted its current name, Strides Pharma Science Limited, in July 2018, having previously been known as Strides Shasun Limited.
Strides Pharma Science Limited is most often compared with the following Healthcare names: